AMG Share Price

Open 155.10 Change Price %
High 156.10 1 Day -3.20 -2.03
Low 153.80 1 Week -1.85 -1.18
Close 154.45 1 Month 11.30 7.89
Volume 3447 1 Year -1.65 -1.06
52 Week High 172.95
52 Week Low 120.65
AMG Important Levels
Resistance 2 156.58
Resistance 1 155.70
Pivot 154.78
Support 1 153.20
Support 2 152.32
ETR Germany Most Active Stocks
DTE 15.46 0.78%
DTE 15.46 0.78%
DTE 15.46 0.78%
DTE 15.46 0.78%
DTE 15.46 0.78%
CBK 11.23 0.18%
CBK 11.23 0.18%
EOAN 9.31 1.20%
EOAN 9.31 1.20%
DBK 13.90 -0.29%
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
MGN 2.96 21.31%
MGN 2.96 21.31%
5M71 39.00 13.70%
R3Q 0.11 10.00%
AB1 0.43 7.50%
TPE 5.09 7.16%
USE 0.15 7.14%
BEO 3.38 6.96%
F3A 43.28 6.63%
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
RLI 21.30 -51.16%
RLI 21.30 -51.16%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
MXW 4.15 -23.15%
ANO 0.08 -11.11%
ANO 0.08 -11.11%

Amgen Inc (ETR: AMG)

AMG Technical Analysis 3
As on 22nd Sep 2017 AMG Share Price closed @ 154.45 and we RECOMMEND Buy for LONG-TERM with Stoploss of 148.19 & Buy for SHORT-TERM with Stoploss of 149.93 we also expect STOCK to react on Following IMPORTANT LEVELS.
AMG Target for September
1st Target up-side 153.1
2nd Target up-side 156.46
3rd Target up-side 159.82
1st Target down-side 143.5
2nd Target down-side 140.14
3rd Target down-side 136.78
AMG Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website
AMG Address
One Amgen Center Drive
Thousand Oaks, CA 91320
United States
Phone: 805-447-1000
Fax: 805-447-1010
AMG Latest News
Interactive Technical Analysis Chart Amgen Inc ( AMG ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Amgen Inc
AMG Business Profile
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company’s principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company’s products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.